CYP2G1P: Key Enzyme in Cytochrome P450 System (G22952)

Target Name: CYP2G1P

NCBI ID: G22952

CYP2G1P

Other Name(s): CYP2G1 | CYP2GP1 | CYP2G2P | Cytochrome P450 family 2 subfamily G member 1, pseudogene | cytochrome P450 family 2 subfamily G member 1, pseudogene

CYP2G1P: Key Enzyme in Cytochrome P450 System

CYP2G1P, also known as CYP2G1, is a protein that is expressed in the liver and other tissues and is involved in the metabolism of many drugs. It is a key enzyme in the cytochrome P450 (CYP) system, which is responsible for breaking down many drugs that are taken to treat a wide range of illnesses.

CYP2G1P is a member of the CYP2G family of enzymes, which are involved in the metabolism of a wide range of drugs. The CYP2G family includes four subfamilies, including CYP2G1, CYP2G2, CYP2G3, and CYP2G4. CYP2G1P is one of the most widely expressed enzymes in the liver and other tissues, and is involved in the metabolism of many drugs, including statins, antidepressants, and benzodiazepines.

CYP2G1P is a key enzyme in the cytochrome P450 (CYP) system, which is responsible for breaking down many drugs that are taken to treat a wide range of illnesses. The CYP2G1P enzyme is involved in the metabolism of many different drugs, including statins, antidepressants, and benzodiazepines.

One of the key functions of CYP2G1P is its role in the metabolism of statins, which are drugs that are used to lower cholesterol levels and reduce the risk of heart disease. CYP2G1P is the enzyme that is responsible for breaking down the active ingredient in statins, which is known as statin-hydroxyacetylated (SHA) groups. These groups are present in the drugs that are used to treat heart disease, and they can interact with the CYP2G1P enzyme in order to affect the way that the drugs are metabolized.

Another function of CYP2G1P is its role in the metabolism of antidepressants, which are drugs that are used to treat depression and other mood disorders. CYP2G1P is involved in the metabolism of the active ingredient in many antidepressants, including fluoxetine (Prozac) and sertraline (Zoloft). These drugs work by altering the levels of certain neurotransmitters in the brain, including serotonin and dopamine.

CYP2G1P is also involved in the metabolism of other drugs, including benzodiazepines, which are drugs that are used to treat anxiety and other disorders. These drugs work by altering the levels of certain neurotransmitters in the brain, including GABA and GABA-尾.

In addition to its role in the metabolism of drugs, CYP2G1P is also involved in the regulation of cellular processes that are important for the survival and function of many different cells. For example, CYP2G1P is involved in the production of reactive oxygen species (ROS), which can damage cells and contribute to a variety of diseases.

Despite its important role in the metabolism of drugs, CYP2G1P is not a drug target (or biomarker) itself. There are many different drugs that are currently being developed to target the CYP2G1P enzyme, in order to treat a wide range of diseases. For example, some researchers are working on developing drugs that can inhibit the activity of CYP2G1P in order to reduce the amount of drugs that are metabolized by this enzyme.

Overall, CYP2G1P is a protein that is widely expressed in the liver and other tissues and is involved in the metabolism of many drugs. It is a key enzyme in the cytochrome P450 (CYP) system and is involved in the production of reactive oxygen species (ROS), which can damage cells

Protein Name: Cytochrome P450 Family 2 Subfamily G Member 1, Pseudogene

The "CYP2G1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2G1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets